Auxilium Pharmaceuticals Inc. (AUXL)
AUXL (NASDAQ:Drugs)
$15.01
-0.04
-0.27%
Today's Range: 14.98 - 15.34 |
AUXL Avg Daily Volume: 785,400
| Last Update: 05/17/13 - 4:00 PM EDT |
| Volume: 828,141 |
| YTD Performance: -18.82%
|
| Open: $15.09 |
| Previous Close: $15.05 |
| 52 Week Range: $13.87 -
$29.37 |
| Oustanding Shares: 49,306,028 |
| Market Cap: 742,055,721 |
6-Month Chart
TheStreet Ratings Grade for AUXL
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
7 |
5 |
6 |
6 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
2 |
3 |
3 |
3 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
1 |
2 |
2 |
2 |
| Mean Rec. |
1.82 |
2.30 |
2.19 |
2.19 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
9.35 |
|
| Price Earnings Comparisons: |
| AUXL |
Sector Avg. |
S&P 500 |
| 9.35 |
9.30 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
-12.30%
|
-18.78%
|
-54.63%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
49.50 |
1.41 |
0.34 |
| Net Income |
0.00 |
-2.61 |
0.00 |
| EPS |
0.00 |
-2.44 |
0.00 |
| Earnings for AUXL: |
| EBITDA |
0.10B |
| Revenue |
0.40B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$-0.07 |
$0.00 |
$-0.02 |
$0.37 |
| Number of Analysts |
3 |
2 |
5 |
5 |
| High Estimate |
$0.12 |
$0.07 |
$0.41 |
$1.38 |
| Low Estimate |
$-0.30 |
$-0.08 |
$-0.51 |
$-0.95 |
| Prior Year |
$0.16 |
$-0.21 |
$1.74 |
$-0.02 |
| Growth Rate (Year over Year) |
-141.67% |
97.62% |
-101.03% |
2,155.56% |
May 03, 2013 | 8:26 AM EDT
AUXL was upgraded from Underweight to Equal-weight, Morgan Stanley said. Risk/reward is more attractive, following a 50% decline since ...
Nov 29, 2012 | 6:00 AM EST
Portfolio Mgr. David Peltier analyzes a volatile, low-dollar drug stock.
Nov 08, 2012 | 8:22 AM EST
Shares of AUXL now seen reaching $29, Jefferies said. Estimates also lowered on Testim miss. Buy rating.
Aug 29, 2012 | 6:00 AM EDT
Portfolio David Peltier finds a pharma name that's quietly growing faster than its peers.
Aug 01, 2012 | 8:43 AM EDT
Shares of AUXL now seen reaching $32, Jefferies said. Estimates also raised on first quarter results. Buy rating.
Aug 01, 2012 | 8:38 AM EDT
Shares of AUXL now seen reaching $32, UBS said. Estimates also increased as Testim sales ramp should drive upside. Buy rating.
Aug 01, 2012 | 8:03 AM EDT
AUXL was downgraded to Market Perform, Leerink Swann said. Company lacks near-term catalysts. $25 price target.
Jun 05, 2012 | 8:16 AM EDT
Shares of AUXL now seen reaching $30, Jefferies said. Good buying opportunity on positive Peyronie's data. Buy rating.
May 17, 2012 | 7:30 AM EDT
Portfolio Manager David Peltier uncovers a drugmaker that's pulled back to an attractive level.
